肝癌早诊代谢组学研究进展  

Research advances of metabolomics in early diagnosis of hepatocellular carcinoma

作　　者：廖星美 赵思如 戴文聪[1,2] 樊蓉 Liao Xingmei;Zhao Siru;Dai Wencong;Fan Rong(Department of Infectious Diseases and Hepatology Unit,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China;The first School of Clinical Medicine,Southern Medical University,Guangdong Provincial Key Laboratory of Viral Hepatitis Research,Guangzhou 510515,China)

机构地区：[1]南方医科大学南方医院肝病中心暨感染内科,广州510515 [2]南方医科大学第一临床医学院,广东省病毒性肝炎研究重点实验室,广州510515

出　　处：《中华肝脏病杂志》2022年第8期803-808,共6页Chinese Journal of Hepatology

基　　金：国家自然科学基金(82170610)。

摘　　要：原发性肝癌是我国第二大恶性肿瘤致死病因,肝细胞癌(HCC)是其主要类型。诊断HCC时的疾病分期很大程度上决定了后续治疗的疗效。由于我国尚未在肝癌高危人群中普及肝癌早筛工作,且受限于当前肝癌早诊手段,我国肝癌早诊率不足30%。近年来,代谢组学逐渐兴起,在HCC的发生机制、早期预防和诊断、药物治疗靶点等多个领域的研究都取得新进展,同时发掘出众多具有优良灵敏度和特异度的血清代谢物指标,弥补了传统血清学指标的不足,助力HCC的早筛早诊。现总结近5年HCC血清代谢组学标志物研究,探讨代谢组学在HCC的早期预测诊断中的价值以及应用前景。Primary liver cancer is the second leading cause of death from malignant tumors in China,and hepatocellular carcinoma(HCC)is the main type.The disease stage at the time of HCC diagnosis largely determines the efficacy of subsequent treatment.Due to the HCC screening among high-risk population has not yet popularized,and the current diagnose method of early HCC is not satisfactory,the early HCC diagnosis rate is less than 30%in China.Metabolomics research emerging in recent years has promoted the research progress of HCC in many fields,such as elaborating the mechanism of occurrence and development,early prevention and diagnosis,exploring drug treatment targets.At the same time,a large number of serum metabolites with excellent sensitivity and specificity were discovered,which made up for the deficiency of traditional serological indicators and helped the early screening and early diagnosis of HCC.This review will summarize the studies on serum metabolomic markers of HCC in recent 5 years,explore the role of metabolomics in the early prediction and diagnosis of HCC and its application prospect.

关 键 词：肝细胞癌 代谢组学 血清标志物 

分 类 号：R735.7[医药卫生—肿瘤]